Antibe Therapeutics Inc.

Antibe Therapeutics to Present at 2021 Bloom Burton & Co. Healthcare Investor Conference

Retrieved on: 
Wednesday, April 14, 2021
Biotechnology, Pharmaceutical, Health, Finance, Money, Financial regulation, Banking in Canada, Canadian Investor Protection Fund, Economy, Investment Industry Regulatory Organization of Canada, Security, Burton, Antibe Therapeutics Inc., Bloom Burton & Co.

Following the presentation, a replay of the webcast will be available for 90 days.\nThe Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector.

Key Points: 
  • Following the presentation, a replay of the webcast will be available for 90 days.\nThe Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector.
  • Learn more at antibethera.com .\nAbout Bloom Burton & Co.\nBloom Burton & Co. (Bloom Burton Securities Inc.) is a firm dedicated to accelerating returns in the healthcare sector for both investors and companies.
  • Bloom Burton and its affiliates provide capital raising, M&A advisory, equity research, business strategy and scientific consulting, advisory on direct investing and company creation and incubation services.
  • Bloom Burton Securities Inc. is a member of the Investment Industry Regulatory Organization of Canada (IIROC) and is also a member of the Canadian Investor Protection Fund (CIPF).\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210414005233/en/\n'

Antibe Therapeutics Announces Strategic Licensing Deal in China With Nuance Pharma

Retrieved on: 
Tuesday, February 9, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Antibe Therapeutics, Nuance, Antibe Therapeutics Inc., Nuance Pharma

Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF) today announced that it has licensed otenaproxesul to Nuance Pharma for commercialization in the Greater China region.

Key Points: 
  • Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF) today announced that it has licensed otenaproxesul to Nuance Pharma for commercialization in the Greater China region.
  • Nuance is a biopharmaceutical company focused on licensing, developing and commercializing globally innovative therapies to address critical unmet medical needs in China and other Asia Pacific markets.
  • Antibe and Nuance have established a structure for collaborating on otenaproxesuls clinical development in the region, ensuring a fit with Antibes global regulatory strategy.
  • We are very impressed with Nuances strategic grasp of the dynamics and opportunities in Chinas pharma marketplace, commented Dan Legault, Antibes CEO.

Antibe Therapeutics Announces Positive Top-Line Data From Phase 2B Dose-Ranging, Efficacy Study For ATB-346

Retrieved on: 
Monday, June 1, 2020
General Health, Pharmaceutical, Health, Clinical trials, Clinical research, Deception, Placebo, Articles, ATB-346, Antibe Therapeutics Inc.

We are pleased that our drug provided excellent pain relief to the patients in the study, remarked Dan Legault, Antibes CEO.

Key Points: 
  • We are pleased that our drug provided excellent pain relief to the patients in the study, remarked Dan Legault, Antibes CEO.
  • The success of this study is a worthy complement to the GI safety results already in hand.
  • Similar efficacy was observed between these doses, suggesting that the upper range of the dose-response curve has been reached.
  • Antibe anticipates that this efficacy trial will compare multiple doses of ATB-346 to placebo in OA patients over a 12-week period.

Antibe Therapeutics Provides Corporate Update and Reports Q2 2020 Interim Financial and Operating Results

Retrieved on: 
Thursday, November 28, 2019
Professional services, Health, Finance, Banking, Pharmaceutical, Biotechnology, Antibe Therapeutics, System for Electronic Document Analysis and Retrieval, Forward-looking statement, OTC Markets Group, Prospectus, Sedar, Financial statement, Companies, Information, Economy, ATB-346, Antibe Therapeutics Inc.

Antibe Therapeutics Inc. ("Antibe" or the Company) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to provide a corporate update in conjunction with the filing of its financial and operating results for the fiscal quarter ended September 30, 2019.

Key Points: 
  • Antibe Therapeutics Inc. ("Antibe" or the Company) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to provide a corporate update in conjunction with the filing of its financial and operating results for the fiscal quarter ended September 30, 2019.
  • Antibe reported a cash balance at September 30, 2019, of $8 million, which reflects the successful prospectus offering that was concluded in August.
  • The Companys unaudited fiscal Q2 2020 condensed interim consolidated financial statements and MD&A will be available on SEDAR today.
  • Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.